PPAR-α Agonist Improves Hyperglycemia-Induced Oxidative Stress in Pancreatic Cells by Potentiating Antioxidant Defense System

Abstract

Background Diabetes-induced oxidative stress has an essential role in pancreatic cells dysfunction. The present study aimed to evaluate whether peroxisome proliferator activated receptor- alpha (PPAR-α) induction by fenofibrate counterbalances oxidative stress in pancreatic cells.

Methods In this in vivo study, male Wistar rats were randomly divided into four groups as normal, normal treated, diabetic and diabetic treated groups (n=6 in each group). Diabetes was induced by a single intravenous injection of streptozotocin (45 mg/kg). Treated animals received fenofibrate for 8 weeks (80 mg/kg/day) orally. At the end of the 8^th week, rats were sacrificed and blood samples and pancreas tissues were collected. Then, the content of malondialdehyde (MDA), nitrate (Nox) and glutathione (GLT) and enzymatic activities of catalase (CAT) and superoxide dismutase (SOD) were assessed. D ata were analyzed using two-way ANOVA.

Results Diabetes deteriorated anti-oxidant defense capacity in pancreatic cells by reducing SOD and CAT activities and induced oxidative stress as reflected by increased MDA content and free radicals production (Nox content). Treatment by fenofibrate increased SOD and CAT activities and improved oxidative stress by decreasing pancreatic MDA and Nox levels.

Conclusion Uncontrolled hyperglycemia weakens anti-oxidant defense capacity in pancreatic cells and contributes to oxidative stress. PPAR-α induction by fenofibrate can restore anti-oxidant defense systems and improve diabetes-induced oxidative stress.

Key words

oxidative stress - pancreas - PPAR-α - diabetes

• References

• 1 Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circulation research 2010; 107: 1058-1070
• 2 Nishikawa T, Edelstein D, Du XL. et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000; 404: 787
• 3 Domingueti CP, Dusse LMS, Carvalho MDG. et al. Diabetes mellitus: The linkage between oxidative stress, inflammation, hypercoagulability and vascular complications. Journal of Diabetes and its Complications 2016; 30: 738-745
• 4 Gerber PA, Rutter GA. The role of oxidative stress and hypoxia in pancreatic beta-cell dysfunction in diabetes mellitus. Antioxidants and Redox Signaling 2017; 26: 501-518
• 5 Hasnain SZ, Prins JB, McGuckin MA. Oxidative and endoplasmic reticulum stress in β-cell dysfunction in diabetes. Journal of Molecular Endocrinology 2016; 56: R33-R54
• 6 Grankvist K, Marklund SL, Täljedal I. CuZn-superoxide dismutase, Mn-superoxide dismutase, catalase and glutathione peroxidase in pancreatic islets and other tissues in the mouse. Biochemical Journal 1981; 199: 393-398
• 7 Tiedge M, Lortz S, Drinkgern J. et al. Relation between antioxidant enzyme gene expression and antioxidative defense status of insulin-producing cells. Diabetes 1997; 46: 1733-1742
• 8 Robertson RP. Chronic oxidative stress as a central mechanism for glucose toxicity in pancreatic islet beta cells in diabetes. Journal of Biological Chemistry 2004; 279: 42351-42354
• 9 Xu B, Moritz JT, Epstein PN. Overexpression of catalase provides partial protection to transgenic mouse beta cells. Free Radical Biology and Medicine 1999; 27: 830-837
• 10 Kajimoto Y, Kaneto H. Role of Oxidative Stress in Pancreatic β-Cell Dysfunction. Annals of the New York Academy of Sciences 2004; 1011: 168-176
• 11 Kaneto H, Xu G, Fujii N. et al. Involvement of c-Jun N-terminal kinase in oxidative stress-mediated suppression of insulin gene expression. The Journal of biological chemistry 2002; 277: 30010-30018
• 12 LeRoith D, Taylor SI, Olefsky JM. Diabetes mellitus: A fundamental and clinical text. Lippincott Williams & Wilkins; 2004
• 13 Telek G, Ducroc R, Scoazec J-Y. et al. Differential upregulation of cellular adhesion molecules at the sites of oxidative stress in experimental acute pancreatitis. Journal of Surgical Research 2001; 96: 56-67
• 14 Yu JH, Kim H. Oxidative stress and inflammatory signaling in cerulein pancreatitis. World Journal of Gastroenterology 2014; 20: 17324-17329
• 15 Armstrong JA, Cash N, Soares PM. et al. Oxidative stress in acute pancreatitis: Lost in translation?. Free radical research 2013; 47: 917-933
• 16 Finegood DT, McArthur MD, Kojwang D. et al. β-cell mass dynamics in Zucker Diabetic Fatty rats. Diabetes 2001; 50: 1021-1029
• 17 Derosa G, Maffioli P, Sahebkar A. Plasma uric acid concentrations are reduced by fenofibrate: A systematic review and meta-analysis of randomized placebo-controlled trials. Pharmacological research 2015; 102: 63-70
• 18 Sahebkar A, Giua R, Pedone C. et al. Fibrate therapy and flow-mediated dilation: A systematic review and meta-analysis of randomized placebo-controlled trials. Pharmacological research 2016; 111: 163-179
• 19 Sahebkar A, Serban MC, Mikhailidis DP. et al. Lipid, G. Blood Pressure Meta-analysis Collaboration, Head-to-head comparison of statins versus fibrates in reducing plasma fibrinogen concentrations: A systematic review and meta-analysis. Pharmacological research 2016; 103: 236-252
• 20 Sahebkar A, Watts GF. Fibrate therapy and circulating adiponectin concentrations: A systematic review and meta-analysis of randomized placebo-controlled trials. Atherosclerosis 2013; 230: 110-120
• 21 Sahebkar A, Simental-Mendia LE, Watts GF. et al. Lipid, G. Blood Pressure Meta-analysis Collaboration, Comparison of the effects of fibrates versus statins on plasma lipoprotein(a) concentrations: A systematic review and meta-analysis of head-to-head randomized controlled trials. BMC medicine 2017; 15: 22
• 22 Liu Q, Li J, Liu Z. et al. Salutary effect of fenofibrate on diabetic retinopathy via inhibiting oxidative stress-mediated wnt pathway activation. Investigative Ophthalmology & Visual Science 2014; 55: 1027-1027
• 23 Rosenson RS, Wolff DA, Huskin AL. et al. Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome. Diabetes Care 2007; 30: 1945-1951
• 24 Hou X, Shen YH, Li C. et al. PPARα agonist fenofibrate protects the kidney from hypertensive injury in spontaneously hypertensive rats via inhibition of oxidative stress and MAPK activity. Biochemical and biophysical research communications 2010; 394: 653-659
• 25 Harano Y, Yasui K, Toyama T. et al. Fenofibrate, a peroxisome proliferator-activated receptor α agonist, reduces hepatic steatosis and lipid peroxidation in fatty liver Shionogi mice with hereditary fatty liver. Liver International 2006; 26: 613-620
• 26 Hu D, Su C, Jiang M. et al. Fenofibrate inhibited pancreatic cancer cells proliferation via activation of p53 mediated by upregulation of LncRNA MEG3. Biochemical and biophysical research communications 2016; 471: 290-295
• 27 Sun Y, Ren M, GONG B. et al. Chronic palmitate exposure inhibits AMPKα and decreases glucose-stimulated insulin secretion from β-cells: modulation by fenofibrate. Acta pharmacologica Sinica 2008; 29: 443-450
• 28 Park C, Zhang Y, Zhang X. et al. PPARα agonist fenofibrate improves diabetic nephropathy in db/db mice. Kidney international 2006; 69: 1511-1517
• 29 El-Wakil H, Aboushousha T, El Haddad O. et al. Effect of schistosoma mansoni egg deposition on multiple low doses streptozotocin induced insulin dependent diabetes. Journal of the Egyptian Society of Parasitology 2002; 32: 987-1002
• 30 Winterbourn CC, Hawkins RE, Brian M. et al. The estimation of red cell superoxide dismutase activity. The Journal of laboratory and clinical medicine 1975; 85: 337-341
• 31 Aebi H. [13] Catalase in vitro. Methods in enzymology 1984; 105: 121-126
• 32 Tietze F. Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: Applications to mammalian blood and other tissues. Analytical biochemistry 1969; 27: 502-522
• 33 Satoh M, Fujimoto S, Haruna Y. et al. NAD (P) H oxidase and uncoupled nitric oxide synthase are major sources of glomerular superoxide in rats with experimental diabetic nephropathy. American Journal of Physiology-Renal Physiology 2005; 288: F1144-F1152
• 34 Granger DL, Taintor RR, Boockvar KS. et al. Measurement of nitrate and nitrite in biological samples using nitrate reductase and Griess reaction. Methods 1996; 268: 142-151
• 35 Lenzen S, Drinkgern J, Tiedge M. Low antioxidant enzyme gene expression in pancreatic islets compared with various other mouse tissues. Free Radical Biology and Medicine 1996; 20: 463-466
• 36 Sindhu RK, Koo JR, Roberts CK. et al. Dysregulation of hepatic superoxide dismutase, catalase and glutathione peroxidase in diabetes: response to insulin and antioxidant therapies. Clinical and experimental hypertension 2004; 26: 43-53
• 37 Çekiç O, Bardak Y, Totan Y. et al. Superoxide dismutase, catalase, glutathione peroxidase and xanthine oxidase in diabetic rat lenses. Ophthalmic research 1999; 31: 346-350
• 38 Soon Y, Tan B. Evaluation of the hypoglycemic and anti-oxidant activities of Morinda officinalis in streptozotocin-induced diabetic rats. Singapore medical journal 2002; 43: 077-085
• 39 Robertson RP, Harmon JS. Diabetes, glucose toxicity, and oxidative stress: a case of double jeopardy for the pancreatic islet β cell. Free Radical Biology and Medicine 2006; 41: 177-184
• 40 Esmaeili MA, Yadav S, Gupta RK. et al. Preferential PPAR-α activation reduces neuroinflammation, and blocks neurodegeneration in vivo. Human molecular genetics 2015; 25: 317-327
• 41 Walker AE, Kaplon RE, Lucking SMS. et al. Fenofibrate improves vascular endothelial function by reducing oxidative stress while increasing endothelial nitric oxide synthase in healthy normolipidemic older adultsnovelty and significance. Hypertension 2012; 60: 1517-1523
• 42 Liu X, Jang SS, An Z. et al. Fenofibrate decreases radiation sensitivity via peroxisome proliferator-activated receptor α-mediated superoxide dismutase induction in HeLa cells. Radiation oncology journal 2012; 30: 88-95
• 43 Wang G, Liu X, Guo Q. et al. Chronic treatment with fibrates elevates superoxide dismutase in adult mouse brain microvessels. Brain research 2010; 1359: 247-255
• 44 Sahebkar A, Chew GT, Watts GF. New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease. Expert opinion on pharmacotherapy 2014; 15: 493-503
• 45 Sahebkar A, Watts GF. Role of selective peroxisome proliferator-activated receptor modulators in managing cardiometabolic disease: tale of a roller-coaster, Diabetes. Obesity and Metabolism 2014; 16: 780-792